Jian-Bin Su1, Yun-Yu Wu2, Feng Xu3, Xing Wang3, Hong-Li Cai4, Li-Hua Zhao3, Xiu-Lin Zhang5, Tong Chen5, Hai-Yan Huang3, Xue-Qin Wang6. 1. Department of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People's Hospital of Nantong City, No. 6, Haierxiang North Road, Nantong, 226001, China. sujbzjx@163.com. 2. Medical School of Nantong University, No. 19, Qixiu Road, Nantong, 226001, China. 3. Department of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People's Hospital of Nantong City, No. 6, Haierxiang North Road, Nantong, 226001, China. 4. Department of Geriatrics, Affiliated Hospital 2 of Nantong University, and First People's Hospital of Nantong City, No. 6 North Haierxiang Road, Nantong, 226001, China. 5. Department of Clinical Laboratory, Affiliated Hospital 2 of Nantong University, and First People's Hospital of Nantong City, No. 6, Haierxiang North Road, Nantong, 226001, China. 6. Department of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People's Hospital of Nantong City, No. 6, Haierxiang North Road, Nantong, 226001, China. wangxueqin108@163.com.
Abstract
PURPOSE: Serum complement C3 has been shown to contribute to the incidence of type 2 diabetes (T2D), but how serum complement C3 affects islet β-cell function throughout the course of T2D is unclear. This study explored whether serum complement C3 is independently associated with changes in islet β-cell function over time in patients with T2D. METHODS: Serum complement C3 was measured, and endogenous β-cell function was evaluated by area under the C-peptide curve (AUCcp) during an oral glucose tolerance test (OGTT) in 411 patients with T2D at baseline from 2011 to 2015. Next, 347 of those patients with available data were pooled for a final follow-up analysis from 2014 to 2018. Changes in islet β-cell function at follow-up were evaluated by AUCcp percentage changes (ΔAUCcp%). In addition, other possible clinical risks for diabetes were also examined. RESULTS: The 347 patients included in the analysis had a diabetes duration of 4.84 ± 3.63 years at baseline. Baseline serum complement C3 (baseline C3) levels were positively correlated with baseline natural logarithm of AUCcp (lnAUCcp) (n = 347, r = 0.288, p < 0.001), and baseline C3 was independently associated with baseline lnAUCcp (β = 0.17, t = 3.52, p < 0.001) after adjustment for baseline glycemic status and other clinical confounders by multivariate liner regression analysis. Compared with the baseline values, complement C3 changes (ΔC3) and ΔAUCcp% was -0.15 ± 0.28 mg/ml and -17.2 ± 18.4%, respectively, at a follow-up visit 4.57 ± 0.78 years later. Moreover, ΔC3 was positively correlated with ΔAUCcp% (n = 347, r = 0.302, p < 0.001). Furthermore, each 0.1 mg/ml increase in ΔC3 was associated with a higher ΔAUCcp% (1.41% [95% CI, 0.82-2.00%]) after adjusting for changes in glycemic status and other clinical confounders at follow-up. CONCLUSIONS: In addition to serum complement C3 being independently associated with islet β-cell function at baseline, its changes were also independently associated with changes in islet β-cell function over time in patients with T2D.
PURPOSE: Serum complement C3 has been shown to contribute to the incidence of type 2 diabetes (T2D), but how serum complement C3 affects islet β-cell function throughout the course of T2D is unclear. This study explored whether serum complement C3 is independently associated with changes in islet β-cell function over time in patients with T2D. METHODS: Serum complement C3 was measured, and endogenous β-cell function was evaluated by area under the C-peptide curve (AUCcp) during an oral glucose tolerance test (OGTT) in 411 patients with T2D at baseline from 2011 to 2015. Next, 347 of those patients with available data were pooled for a final follow-up analysis from 2014 to 2018. Changes in islet β-cell function at follow-up were evaluated by AUCcp percentage changes (ΔAUCcp%). In addition, other possible clinical risks for diabetes were also examined. RESULTS: The 347 patients included in the analysis had a diabetes duration of 4.84 ± 3.63 years at baseline. Baseline serum complement C3 (baseline C3) levels were positively correlated with baseline natural logarithm of AUCcp (lnAUCcp) (n = 347, r = 0.288, p < 0.001), and baseline C3 was independently associated with baseline lnAUCcp (β = 0.17, t = 3.52, p < 0.001) after adjustment for baseline glycemic status and other clinical confounders by multivariate liner regression analysis. Compared with the baseline values, complement C3 changes (ΔC3) and ΔAUCcp% was -0.15 ± 0.28 mg/ml and -17.2 ± 18.4%, respectively, at a follow-up visit 4.57 ± 0.78 years later. Moreover, ΔC3 was positively correlated with ΔAUCcp% (n = 347, r = 0.302, p < 0.001). Furthermore, each 0.1 mg/ml increase in ΔC3 was associated with a higher ΔAUCcp% (1.41% [95% CI, 0.82-2.00%]) after adjusting for changes in glycemic status and other clinical confounders at follow-up. CONCLUSIONS: In addition to serum complement C3 being independently associated with islet β-cell function at baseline, its changes were also independently associated with changes in islet β-cell function over time in patients with T2D.
Entities:
Keywords:
Complement C3; Type 2 diabetes; β-Cell function
Authors: X Bao; Y Xia; Q Zhang; H M Wu; H M Du; L Liu; C J Wang; H B Shi; X Y Guo; X Liu; C L Li; Q Su; G Meng; B Yu; S M Sun; X Wang; M Zhou; Q Y Jia; K Song; K J Niu Journal: Diabet Med Date: 2015-07-02 Impact factor: 4.359
Authors: James C Lo; Sanda Ljubicic; Barbara Leibiger; Matthias Kern; Ingo B Leibiger; Tilo Moede; Molly E Kelly; Diti Chatterjee Bhowmick; Incoronata Murano; Paul Cohen; Alexander S Banks; Melin J Khandekar; Arne Dietrich; Jeffrey S Flier; Saverio Cinti; Matthias Blüher; Nika N Danial; Per-Olof Berggren; Bruce M Spiegelman Journal: Cell Date: 2014-07-03 Impact factor: 41.582
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Maciej M Markiewski; Dimitrios Mastellos; Ruxandra Tudoran; Robert A DeAngelis; Christoph W Strey; Silvia Franchini; Rick A Wetsel; Anna Erdei; John D Lambris Journal: J Immunol Date: 2004-07-15 Impact factor: 5.422
Authors: Ben C King; Klaudia Kulak; Ulrika Krus; Rebecca Rosberg; Ewelina Golec; Katarzyna Wozniak; Maria F Gomez; Enming Zhang; David J O'Connell; Erik Renström; Anna M Blom Journal: Cell Metab Date: 2018-10-04 Impact factor: 27.287
Authors: Nicolas S Merle; Sarah Elizabeth Church; Veronique Fremeaux-Bacchi; Lubka T Roumenina Journal: Front Immunol Date: 2015-06-02 Impact factor: 7.561